Project profile — Global Drug Facility: Provision of Anti-Tuberculosis Drugs

• Africa, regional (35.00%)
• America, regional (1.00%)
• Asia, regional (61.00%)
• Europe, regional (3.00%)

• Basic Health: Tuberculosis control (12263) (100.00%)

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (not targeted)

This grant represents part of Canada’s contribution to the Global Drug Facility (GDF), a program of the Stop TB Partnership. It provides access to anti-tuberculosis (TB) drugs for governments that agree to introduce, expand, or maintain the diagnostic, treatment, and monitoring policies of the DOTS (directly observed treatment, short-term) strategy. Launched in 2001, the GDF works to improve the supply, distribution, and monitoring of anti-TB drugs in developing countries and is the only global bulk procurer of anti-TB drugs. Canada was the founding donor of the GDF and to date (2010) has been the single largest donor country for first-line TB drugs. The GDF is a four-pronged mechanism whereby: (1) countries who cannot afford to procure all the anti-TB drug they need are eligible to apply for drugs for up to six years (DFATD provides funding for this component); (2) countries who can pay for the anti-TB drugs they need but cannot assure the quality of the drugs can directly procure them through the GDF at reduced bulk prices (DFATD funding does not contribute to this component); (3) countries where the procurement system is weak can receive technical assistance to strengthen their capacity for drug procurement (DFATD supports this component); and (4) Global Fund recipient countries can procure anti-TB drugs directly through GDF, using Global Fund monies, to ensure a stable and high-quality drug supply.

N/A

Results achieved by Global Drug Facility, through the support of the Government of Canada and other international donors, as of March 2016 include: (1) provided quality-assured treatments since 2001 for more than 27 million patients with tuberculosis (TB), This included over 184,000 patient treatments for multi-drug resistant TB (MDR-TB) and 1.5 million treatments for children; (2) delivered over 1.5 million patient treatments, including over 219,000 pediatric treatments in 2015; (3) provided capacity-building support to 134 countries since 2001, including training and workshops, monitoring missions and technical assistance to improve the management of drug supplies; (4) contributed to planning and guidance for the global introduction of new child-friendly medicines for pediatric TB; and (5) provided a mechanism for countries to order the new pediatric formulations and made grants available to eligible countries to purchase pediatric TB medicines with funding from Global Affairs Canada.

• Proactive disclosure